{"title":"循环 miR-29 家族对消化系统恶性肿瘤的诊断价值：一项元分析","authors":"Shuhui Zou, Fei Chen, Liqin Zhang, Cong Liu, Huamin Chen","doi":"10.1093/labmed/lmad030","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the diagnostic value of circulating microRNA-29 (miR-29) in digestive system malignant neoplasms by meta-analysis.</p><p><strong>Methods: </strong>We searched the PubMed, Embase, Cochrane Library, and Web of Science to collect studies, published through September 2022, on the diagnostic value of miR-29 in digestive system tumors.</p><p><strong>Results: </strong>We included 7 studies in this meta-analysis, including colorectal cancer, esophageal squamous cell carcinomas, and cholangiocarcinoma. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.64 (95% CI, 0.53-0.74), 0.83 (0.60-0.94), 3.75 (1.42-9.91), 0.44 (0.31-0.61), and 8.63 (2.54-29.26), respectively. The area under the summary receiver operating characteristic curve was 0.75. The sensitivity of miR-29 derived from serum was higher than that of miR-29 derived from plasma for malignant digestive system tumors (0.71 vs 0.54; P = .04).</p><p><strong>Conclusion: </strong>This meta-analysis suggests that the circulating miR-29 family has good diagnostic performance for digestive system malignant tumors, with moderate sensitivity and good specificity.</p>","PeriodicalId":17951,"journal":{"name":"Laboratory medicine","volume":" ","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Diagnostic Value of Circulating miR-29 Family for Digestive System Malignancies: A Meta-Analysis.\",\"authors\":\"Shuhui Zou, Fei Chen, Liqin Zhang, Cong Liu, Huamin Chen\",\"doi\":\"10.1093/labmed/lmad030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the diagnostic value of circulating microRNA-29 (miR-29) in digestive system malignant neoplasms by meta-analysis.</p><p><strong>Methods: </strong>We searched the PubMed, Embase, Cochrane Library, and Web of Science to collect studies, published through September 2022, on the diagnostic value of miR-29 in digestive system tumors.</p><p><strong>Results: </strong>We included 7 studies in this meta-analysis, including colorectal cancer, esophageal squamous cell carcinomas, and cholangiocarcinoma. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.64 (95% CI, 0.53-0.74), 0.83 (0.60-0.94), 3.75 (1.42-9.91), 0.44 (0.31-0.61), and 8.63 (2.54-29.26), respectively. The area under the summary receiver operating characteristic curve was 0.75. The sensitivity of miR-29 derived from serum was higher than that of miR-29 derived from plasma for malignant digestive system tumors (0.71 vs 0.54; P = .04).</p><p><strong>Conclusion: </strong>This meta-analysis suggests that the circulating miR-29 family has good diagnostic performance for digestive system malignant tumors, with moderate sensitivity and good specificity.</p>\",\"PeriodicalId\":17951,\"journal\":{\"name\":\"Laboratory medicine\",\"volume\":\" \",\"pages\":\"1-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Laboratory medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/labmed/lmad030\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/labmed/lmad030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的通过荟萃分析评估循环microRNA-29（miR-29）在消化系统恶性肿瘤中的诊断价值：我们检索了 PubMed、Embase、Cochrane Library 和 Web of Science，收集了截至 2022 年 9 月发表的有关 miR-29 在消化系统肿瘤中诊断价值的研究：本次荟萃分析共纳入了7项研究，包括结直肠癌、食管鳞状细胞癌和胆管癌。汇总的敏感性、特异性、阳性似然比、阴性似然比和诊断几率比分别为0.64（95% CI，0.53-0.74）、0.83（0.60-0.94）、3.75（1.42-9.91）、0.44（0.31-0.61）和8.63（2.54-29.26）。接收者操作特征曲线下的面积为 0.75。血清中的 miR-29 对恶性消化系统肿瘤的敏感性高于血浆中的 miR-29（0.71 vs 0.54；P = .04）：这项荟萃分析表明，循环中的miR-29家族对消化系统恶性肿瘤具有良好的诊断性能，灵敏度适中，特异性良好。
The Diagnostic Value of Circulating miR-29 Family for Digestive System Malignancies: A Meta-Analysis.
Objective: To evaluate the diagnostic value of circulating microRNA-29 (miR-29) in digestive system malignant neoplasms by meta-analysis.
Methods: We searched the PubMed, Embase, Cochrane Library, and Web of Science to collect studies, published through September 2022, on the diagnostic value of miR-29 in digestive system tumors.
Results: We included 7 studies in this meta-analysis, including colorectal cancer, esophageal squamous cell carcinomas, and cholangiocarcinoma. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.64 (95% CI, 0.53-0.74), 0.83 (0.60-0.94), 3.75 (1.42-9.91), 0.44 (0.31-0.61), and 8.63 (2.54-29.26), respectively. The area under the summary receiver operating characteristic curve was 0.75. The sensitivity of miR-29 derived from serum was higher than that of miR-29 derived from plasma for malignant digestive system tumors (0.71 vs 0.54; P = .04).
Conclusion: This meta-analysis suggests that the circulating miR-29 family has good diagnostic performance for digestive system malignant tumors, with moderate sensitivity and good specificity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
